Testing the estrogen hypothesis of schizophrenia: Associations between cumulative estrogen exposure and cerebral structural measures

Schizophrenia Research

Volumn 150, Issue 1, 2013, Pages 114-120

  van der Leeuw, C ^a   Habets, P ^a   Gronenschild, E ^a   Domen, P ^a   Michielse, S ^a   van Kroonenburgh, M ^a   van Os, J ^a,b   Marcelis, M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Bone mineral density; Cortical thickness; Diffusion tensor imaging; Estrogen; Fractional anisotropy; Gray matter; Psychotic disorder; Schizophrenia; Structural imaging; White matter

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CONTRACEPTIVE AGENT; ESTROGEN; HALOPERIDOL; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BONE DENSITY; CORTICAL THICKNESS (BRAIN); DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; FRACTIONAL ANISOTROPY; GRAY MATTER; HORMONE RESPONSE; HUMAN; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; WHITE MATTER;

BONE MINERAL DENSITY; CORTICAL THICKNESS; DIFFUSION TENSOR IMAGING; ESTROGEN; FRACTIONAL ANISOTROPY; GRAY MATTER; PSYCHOTIC DISORDER; SCHIZOPHRENIA; STRUCTURAL IMAGING; WHITE MATTER;

ABSORPTIOMETRY, PHOTON; ADULT; BONE DENSITY; CEREBRAL CORTEX; DIFFUSION TENSOR IMAGING; ESTROGENS; FEMALE; HUMANS; LONGITUDINAL STUDIES; NONLINEAR DYNAMICS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84884142571     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.07.033     Document Type: Article

References (66)

1. Abel K.M., Drake R., Goldstein J.M. Sex differences in schizophrenia. Int. Rev. Psychiatry 2010, 22(5):417-428.
2. Asato M.R., Terwilliger R., Woo J., Luna B. White matter development in adolescence: a DTI study. Cereb. Cortex 2010, 20(9):2122-2131.
3. Aston J., Rechsteiner E., Bull N., Borgwardt S., Gschwandtner U., Riecher-Rossler A. Hyperprolactinaemia in early psychosis-not only due to antipsychotics. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34(7):1342-1344.
4. Azcoitia I., Arevalo M.A., De Nicola A.F., Garcia-Segura L.M. Neuroprotective actions of estradiol revisited. Trends Endocrinol. Metab. 2011, 22(12):467-473.
5. Begemann M.J., Dekker C.F., van Lunenburg M., Sommer I.E. Estrogen augmentation in schizophrenia: a quantitative review of current evidence. Schizophr. Res. 2012, 141(2-3):179-184.
6. Boccardi M., Ghidoni R., Govoni S., Testa C., Benussi L., Bonetti M., Binetti G., Frisoni G.B. Effects of hormone therapy on brain morphology of healthy postmenopausal women: a voxel-based morphometry study. Menopause 2006, 13(4):584-591.
7. Boerma M.A., van der Stel J.C., van Amelsvoort T., Linszen D.H., de Haan L. Women, schizophrenia and oestrogen; neurobiological hypotheses and hormone therapy studies. Tijdschr. Psychiatr 2010, 52(4):235-244.
8. Brann D.W., Dhandapani K., Wakade C., Mahesh V.B., Khan M.M. Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids 2007, 72(5):381-405.
9. Chua W.L., de Izquierdo S.A., Kulkarni J., Mortimer A. Estrogen for schizophrenia. Cochrane Database Syst. Rev. 2005, (4):CD004719.
10. Clemons M., Goss P. Estrogen and the risk of breast cancer. N. Engl. J. Med. 2001, 344(4):276-285.
11. Crews M.P., Howes O.D. Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications. Hum. Psychopharmacol. 2012, 27(1):15-23.
12. Dale A.M., Fischl B., Sereno M.I. Cortical surface-based analysis. I. Segmentation and surface reconstruction. NeuroImage 1999, 9(2):179-194.
13. Desikan R.S., Segonne F., Fischl B., Quinn B.T., Dickerson B.C., Blacker D., Buckner R.L., Dale A.M., Maguire R.P., Hyman B.T., Albert M.S., Killiany R.J. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. NeuroImage 2006, 31(3):968-980.
14. Fischl B., Dale A.M. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(20):11050-11055.
15. Fischl B., Sereno M.I., Dale A.M. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. NeuroImage 1999, 9(2):195-207.
16. Fischl B., Salat D.H., Busa E., Albert M., Dieterich M., Haselgrove C., van der Kouwe A., Killiany R., Kennedy D., Klaveness S., Montillo A., Makris N., Rosen B., Dale A.M. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002, 33(3):341-355.
17. Fischl B., van der Kouwe A., Destrieux C., Halgren E., Segonne F., Salat D.H., Busa E., Seidman L.J., Goldstein J., Kennedy D., Caviness V., Makris N., Rosen B., Dale A.M. Automatically parcellating the human cerebral cortex. Cereb. Cortex 2004, 14(1):11-22.
18. Friston K.J. The disconnection hypothesis. Schizophr. Res. 1998, 30(2):115-125.
19. Goldstein H. Multilevel Models in Educational and Social Research 1987, Griffin, London.
20. Goldstein J.M., Seidman L.J., Horton N.J., Makris N., Kennedy D.N., Caviness V.S., Faraone S.V., Tsuang M.T. Normal sexual dimorphism of the adult human brain assessed by in vivo magnetic resonance imaging. Cereb. Cortex 2001, 11(6):490-497.
21. Goldstein J.M., Seidman L.J., O'Brien L.M., Horton N.J., Kennedy D.N., Makris N., Caviness V.S., Faraone S.V., Tsuang M.T. Impact of normal sexual dimorphisms on sex differences in structural brain abnormalities in schizophrenia assessed by magnetic resonance imaging. Arch. Gen. Psychiatry 2002, 59(2):154-164.
22. Greenberg D.L., Payne M.E., MacFall J.R., Provenzale J.M., Steffens D.C., Krishnan R.R. Differences in brain volumes among males and female hormone-therapy users and nonusers. Psychiatry Res. 2006, 147(2-3):127-134.
23. Ha D.M., Xu J., Janowsky J.S. Preliminary evidence that long-term estrogen use reduces white matter loss in aging. Neurobiol. Aging 2007, 28(12):1936-1940.
24. Habets P., Marcelis M., Gronenschild E., Drukker M., van Os J. Reduced cortical thickness as an outcome of differential sensitivity to environmental risks in schizophrenia. Biol. Psychiatry 2011, 69(5):487-494.
25. Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003, 28(Suppl. 2):17-54.
26. Hafner H., an der Heiden W., Behrens S., Gattaz W.F., Hambrecht M., Loffler W., Maurer K., Munk-Jorgensen P., Nowotny B., Riecher-Rossler A., Stein A. Causes and consequences of the gender difference in age at onset of schizophrenia. Schizophr. Bull. 1998, 24(1):99-113.
27. Halbreich U., Kahn L.S. Hormonal aspects of schizophrenias: an overview. Psychoneuroendocrinology 2003, 28(Suppl. 2):1-16.
28. Herting M.M., Maxwell E.C., Irvine C., Nagel B.J. The impact of sex, puberty, and hormones on white matter microstructure in adolescents. Cereb. Cortex 2011, 22(9):1979-1992.
29. Ho B.C., Andreasen N.C., Ziebell S., Pierson R., Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry 2011, 68(2):128-137.
30. Huber T.J., Borsutzky M., Schneider U., Emrich H.M. Psychotic disorders and gonadal function: evidence supporting the oestrogen hypothesis. Acta Psychiatr. Scand. 2004, 109(4):269-274.
31. Kanaan R., Barker G., Brammer M., Giampietro V., Shergill S., Woolley J., Picchioni M., Toulopoulou T., McGuire P. White matter microstructure in schizophrenia: effects of disorder, duration and medication. Br. J. Psychiatry 2009, 194(3):236-242.
32. Konrad A., Winterer G. Disturbed structural connectivity in schizophrenia primary factor in pathology or epiphenomenon?. Schizophr. Bull. 2008, 34(1):72-92.
33. Korver N., Quee P.J., Boos H.B., Simons C.J., de Haan L. Genetic Risk and Outcome of Psychosis (GROUP), a multi site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. Int. J. Methods Psychiatr. Res. 2012, 21(3):205-221.
34. Kulkarni J., Gurvich C., Lee S.J., Gilbert H., Gavrilidis E., de Castella A., Berk M., Dodd S., Fitzgerald P.B., Davis S.R. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 2010, 35(8):1142-1147.
35. Kulkarni J., Hayes E., Gavrilidis E. Hormones and schizophrenia. Curr. Opin. Psychiatry 2012, 25(2):89-95.
36. Kuperberg G.R., Broome M.R., McGuire P.K., David A.S., Eddy M., Ozawa F., Goff D., West W.C., Williams S.C., van der Kouwe A.J., Salat D.H., Dale A.M., Fischl B. Regionally localized thinning of the cerebral cortex in schizophrenia. Arch. Gen. Psychiatry 2003, 60(9):878-888.
37. Leung M., Cheung C., Yu K., Yip B., Sham P., Li Q., Chua S., McAlonan G. Gray matter in first-episode schizophrenia before and after antipsychotic drug treatment. Anatomical likelihood estimation meta-analyses with sample size weighting. Schizophr. Bull. 2011, 37(1):199-211.
38. Liu M., Kelley M.H., Herson P.S., Hurn P.D. Neuroprotection of sex steroids. Minerva Endocrinol. 2010, 35(2):127-143.
39. Lord C., Engert V., Lupien S.J., Pruessner J.C. Effect of sex and estrogen therapy on the aging brain: a voxel-based morphometry study. Menopause 2010, 17(4):846-851.
40. Low L.F., Anstey K.J., Maller J., Kumar R., Wen W., Lux O., Salonikas C., Naidoo D., Sachdev P. Hormone replacement therapy, brain volumes and white matter in postmenopausal women aged 60-64years. Neuroreport 2006, 17(1):101-104.
41. Mackenzie-Graham A.J., Rinek G.A., Avedisian A., Morales L.B., Umeda E., Boulat B., Jacobs R.E., Toga A.W., Voskuhl R.R. Estrogen treatment prevents gray matter atrophy in experimental autoimmune encephalomyelitis. J. Neurosci. Res. 2012, 90(7):1310-1323.
42. Markham J.A. Sex steroids and schizophrenia. Rev. Endocr. Metab. Disord. 2011, 13(3):187-207.
43. McEwen B.S., Akama K.T., Spencer-Segal J.L., Milner T.A., Waters E.M. Estrogen effects on the brain: actions beyond the hypothalamus via novel mechanisms. Behav. Neurosci. 2012, 126(1):4-16.
44. Mori S., Oishi K., Jiang H., Jiang L., Li X., Akhter K., Hua K., Faria A.V., Mahmood A., Woods R., Toga A.W., Pike G.B., Neto P.R., Evans A., Zhang J., Huang H., Miller M.I., van Zijl P., Mazziotta J. Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template. NeuroImage 2008, 40(2):570-582.
45. Neufang S., Specht K., Hausmann M., Gunturkun O., Herpertz-Dahlmann B., Fink G.R., Konrad K. Sex differences and the impact of steroid hormones on the developing human brain. Cereb. Cortex 2009, 19(2):464-473.
46. Peper J.S., Brouwer R.M., Schnack H.G., van Baal G.C., van Leeuwen M., van den Berg S.M., Delemarre-Van de Waal H.A., Boomsma D.I., Kahn R.S., Hulshoff Pol H.E. Sex steroids and brain structure in pubertal boys and girls. Psychoneuroendocrinology 2009, 34(3):332-342.
47. Peper J.S., Hulshoff Pol H.E., Crone E.A., van Honk J. Sex steroids and brain structure in pubertal boys and girls: a mini-review of neuroimaging studies. Neuroscience 2011, 191:28-37.
48. Peper J.S., van den Heuvel M.P., Mandl R.C., Pol H.E., van Honk J. Sex steroids and connectivity in the human brain: a review of neuroimaging studies. Psychoneuroendocrinology 2011, 36(8):1101-1113.
49. Pletzer B., Kronbichler M., Aichhorn M., Bergmann J., Ladurner G., Kerschbaum H.H. Menstrual cycle and hormonal contraceptive use modulate human brain structure. Brain Res. 2010, 1348:55-62.
50. Protopopescu X., Butler T., Pan H., Root J., Altemus M., Polanecsky M., McEwen B., Silbersweig D., Stern E. Hippocampal structural changes across the menstrual cycle. Hippocampus 2008, 18(10):985-988.
51. Riecher-Rossler A. Oestrogen effects in schizophrenia and their potential therapeutic implications-review. Arch. Womens Ment. Health 2002, 5(3):111-118.
52. Riecher-Rossler A., Hafner H. Schizophrenia and oestrogens-is there an association?. Eur. Arch. Psychiatry Clin. Neurosci. 1993, 242(6):323-328.
53. Riecher-Rossler A., Hafner H. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr. Scand. Suppl. 2000, (407):58-62.
54. Riecher-Rossler A., Hafner H., Stumbaum M., Maurer K., Schmidt R. Can estradiol modulate schizophrenic symptomatology?. Schizophr. Bull. 1994, 20(1):203-214.
55. Robertson D., Craig M., van Amelsvoort T., Daly E., Moore C., Simmons A., Whitehead M., Morris R., Murphy D. Effects of estrogen therapy on age-related differences in gray matter concentration. Climacteric 2009, 12(4):301-309.
56. Rosas H.D., Liu A.K., Hersch S., Glessner M., Ferrante R.J., Salat D.H., van der Kouwe A., Jenkins B.G., Dale A.M., Fischl B. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002, 58(5):695-701.
57. Salat D.H., Buckner R.L., Snyder A.Z., Greve D.N., Desikan R.S., Busa E., Morris J.C., Dale A.M., Fischl B. Thinning of the cerebral cortex in aging. Cereb. Cortex 2004, 14(7):721-730.
58. Salem J.E., Kring A.M. The role of gender differences in the reduction of etiologic heterogeneity in schizophrenia. Clin. Psychol. Rev. 1998, 18(7):795-819.
59. Seeman M.V. Interaction of sex, age, and neuroleptic dose. Compr. Psychiatry 1983, 24(2):125-128.
60. Seeman M.V. The role of estrogen in schizophrenia. J. Psychiatry Neurosci. 1996, 21(2):123-127.
61. Segonne F., Dale A.M., Busa E., Glessner M., Salat D., Hahn H.K., Fischl B. A hybrid approach to the skull stripping problem in MRI. NeuroImage 2004, 22(3):1060-1075.
62. Shepherd A.M., Laurens K.R., Matheson S.L., Carr V.J., Green M.J. Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia. Neurosci. Biobehav. Rev. 2012, 36(4):1342-1356.
63. Smith S.M. Fast robust automated brain extraction. Hum. Brain Mapp. 2002, 17(3):143-155.
64. Smith S.M., Jenkinson M., Johansen-Berg H., Rueckert D., Nichols T.E., Mackay C.E., Watkins K.E., Ciccarelli O., Cader M.Z., Matthews P.M., Behrens T.E. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. NeuroImage 2006, 31(4):1487-1505.
65. van der Leeuw C., Habets P., Domen P., van Kroonenburgh M., van Os J., Marcelis M. Bone mineral density as a marker of cumulative endogenous estrogen exposure: relationship to background genetic risk of psychotic disorder. Schizophr. Res. 2013, 143(1):25-31.
66. van Haren N.E., Schnack H.G., Cahn W., van den Heuvel M.P., Lepage C., Collins L., Evans A.C., Hulshoff Pol H.E., Kahn R.S. Changes in cortical thickness during the course of illness in schizophrenia. Arch. Gen. Psychiatry 2011, 68(9):871-880.